Level Bio (LEVBIO) investor relations material

Executive summary

• Net sales for Q2 2026 reached 9,201 KSEK, up 10% year-over-year; excluding the divested CyberGene, growth was 23%.

• The group completed the sale of CyberGene to Devyser, receiving 12.2 MSEK in Devyser shares, strengthening the balance sheet.

• The operational focus is now on Techtum Lab, aiming to expand as a Nordic distributor in advanced diagnostics and lab technology.

• Result after tax for Q2 was 6,183 KSEK (previous year: -1,447 KSEK), mainly due to a capital gain from the CyberGene sale.

Financial highlights

• Net sales for H1 2026 totaled 18,197 KSEK, a 12% increase year-over-year; excluding CyberGene, growth was 19%.

• Gross margin for Q2 was 46% (52% prior year; 48% excluding CyberGene), and for H1 was 49% (51% prior year; 49% excluding CyberGene).

• Operating result for Q2 was -225 KSEK (prior year: -1,498 KSEK); for H1, -342 KSEK (prior year: -2,392 KSEK).

• Cash flow for Q2 was -1,383 KSEK (213 KSEK prior year); for H1, -2,406 KSEK (480 KSEK prior year).

• Cash and cash equivalents at June 30, 2026, were 78 KSEK (1,558 KSEK prior year); securities holdings valued at 10.7 MSEK.

Outlook and guidance

• The company plans to leverage its strengthened balance sheet and Techtum Lab’s cash flows for organic growth and acquisitions.

• Focus is on expanding Techtum Lab’s presence across the Nordic region, aiming for more recurring revenues from installed instrument base.